Melissa Lechner's group at UCLA identified both CD4+ (Tfh) and CD8+ (Tc1) T cells as drivers of the autoimmune diabetes that arises after anti-PD1 therapy, and showed the nonspecific JAK inhib ruxolitinib could prevent it! Wow. My suspicion is that targeting IFNg-STAT1 alone probably is enough.

One the many advances in this incredible paper by Columbia's Milner and Izar labs shows that GOF variants in PIK3CD are not all that rare, including p.M285T that occurs in 1/8000, and is correlated with autoimmune diseases. There are many more APDS patients lurking out there! #IEI #raredisease

New antifungals are much needed -- 41 of these patients receiving olorofim had coccidioidomycosis. #valleyfever

@elisabethbik.bsky.social re Atl Butte www.kudoboard.com/boards/OMydG...

⚠️ Effective Monday 2/10/25, NIH indirect rate capped at 15%. Applies to existing & future grants.

—> Deep budget cuts & program closures coming to a university near you.

Is this the break the glass moment for university administrators who have been silent so far about the attack on science?

Bravo to Paul Bollyky @pbollyky.bsky.social at Stanford for his lab's paper showing that complementary groups of phage can be mixed to provide broad and effective antimicrobial therapy against Pseudomonas and Staph infections. Brilliant work!
www.nature.com/articles/s41...

Please add me to your next pack. My lab studies inborn errors of immunity and T cells.